Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. | Ther Adv Hematol;13: 20406207221090886, 2022. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.

Paillassa, Jérôme; Safa, Firas; Troussard, Xavier.

Affiliation

Paillassa J; Service des Maladies du Sang, CHU d'Angers, Angers, France.
Safa F; Service des Maladies du Sang, CHU d'Angers, Angers, France.
Troussard X; Laboratoire Hématologie, CHU de Caen Normandie, avenue de Côte de Nacre, 14033 Caen Cedex, France.

Ther Adv Hematol ; 13: 20406207221090886, 2022.

Article in En | MEDLINE | ID: mdl-35450208

Key words

BCR; BTK; hairy cell leukemia; hairy cell leukemia variant; ibrutinib

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ther Adv Hematol Year: 2022 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ther Adv Hematol Year: 2022 Document type: Article Affiliation country: Country of publication: